Amgen (AMGN) Q2 FY25 earnings call

Amgen delivered a strong second quarter, marked by robust volume-driven revenue growth across its diverse portfolio, including significant contributions from rare disease and biosimilars. The company is actively advancing a world-class pipeline, with multiple late-stage programs in obesity, cardiovascular disease, and oncology, while also navigating industry pricing pressures and investing in AI for innovation. Management remains focused on long-term growth and disciplined execution.